Submit to Metabolites Review for Metabolites Propose a Special Issue

Journal Menu

Journal Browser

Analytical Advances and Applications in Clinical Metabolomics

Special Issue Editors
Special Issue Information
Keywords
Published Papers

A special issue of Metabolites (ISSN 2218-1989). This special issue belongs to the section "Advances in Metabolomics".

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 4656

Share This Special Issue

Special Issue Editors

Prof. Dr. Gisele André Baptista Canuto

E-Mail Website
Guest Editor

Analytical Chemistry Department, Federal University of Bahia, Institute of Chem-istry, Salvador 40170-115, BA, Brazil
Interests: metabolomics; sample preparation; mass spectrometry; separation tech-niques; chemometrics; data processing; clinical metabolomics

Prof. Dr. Rafael Garrett Da Costa

E-Mail Website
Guest Editor

Department of Organic Chemistry, Federal University of Rio de Janeiro, Institute of Chemistry, Rio de Janeiro 21941-598, RJ, Brazil
Interests: metabolomics; high-resolution mass spectrometry; liquid-chromatography; chemometrics; data processing; clinical metabolomics

Special Issue Information

Dear Colleagues,

Metabolomics has emerged as a powerful tool to understand the interactions between complex biological organisms and genetic and environmental factors. In order to perform that, sophisticated analytical techniques and bioinformatics are used to elucidate metabolic changes. Metabolites play an important role in human metabolism, such as regulation and signaling, as a precursor of biomolecules (such as peptides and proteins), and biological structure (lipids), among others. Applications in clinical metabolomics have been the focus of interest of many researchers in different areas of knowledge (neurology, cardiology, oncology, among others). The elucidation of the metabolism, the study of disease severity, the search for biomarkers for diagnosis and prognosis, and drug design and development have contributed to improving the conduct of prevention and treatment of diseases, increasing the quality of life of patients. Thus, we would like to invite researchers to submit original papers to this special issue in Metabolites: “Analytical Advances and Applications in Clinical Metabolomics”. This special issue will be dedicated to publish research and review articles covering analytical challenges, advances, and applications in clinical metabolomics.

We welcome and look forward to your submissions.

Dr. Gisele André Baptista Canuto
Dr. Rafael Garrett Da Costa
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

metabolomics
metabonomics
lipidomics
biomarkers
clinical metabolomics
personalized medicine

Published Papers (3 papers)

Download All Papers

Research

Jump to: Review

18 pages, 3547 KiB

Open AccessArticle

Longitudinal Profiling of Fasting Plasma Metabolome in Response to Weight-Loss Interventions in Patients with Morbid Obesity

by Mingjing Chen, Guanhong Miao, Zhiguang Huo, Hao Peng, Xiaoxiao Wen, Stephen Anton, Dachuan Zhang, Gang Hu, Ricky Brock, Phillip J. Brantley and Jinying Zhao

Metabolites 2024, 14(2), 116; https://doi.org/10.3390/metabo14020116 - 10 Feb 2024

Viewed by 1174

Abstract

It is well recognized that patients with severe obesity exhibit remarkable heterogeneity in response to different types of weight-loss interventions. Those who undergo Roux-en-Y gastric bypass (RYGB) usually exhibit more favorable glycemic outcomes than those who receive adjustable gastric banding (BAND) or intensive medical intervention (IMI). The molecular mechanisms behind these observations, however, remain largely unknown. To identify the plasma metabolites associated with differential glycemic outcomes induced by weight-loss intervention, we studied 75 patients with severe obesity (25 each in RYGB, BAND, or IMI). Using untargeted metabolomics, we repeatedly measured 364 metabolites in plasma samples at baseline and 1-year after intervention. Linear regression was used to examine whether baseline metabolites or changes in metabolites are associated with differential glycemic outcomes in response to different types of weight-loss intervention, adjusting for sex, baseline age, and BMI as well as weight loss. Network analyses were performed to identify differential metabolic pathways involved in the observed associations. After correction for multiple testing (q < 0.05), 33 (RYGB vs. IMI) and 28 (RYGB vs. BAND) baseline metabolites were associated with changes in fasting plasma glucose (FPG) or glycated hemoglobin (HbA1c). Longitudinal changes in 38 (RYGB vs. IMI) and 38 metabolites (RYGB vs. BAND) were significantly associated with changes in FPG or HbA1c. The identified metabolites are enriched in pathways involved in the biosynthesis of aminoacyl-tRNA and branched-chain amino acids. Weight-loss intervention evokes extensive changes in plasma metabolites, and the altered metabolome may underlie the differential glycemic outcomes in response to different types of weight-loss intervention, independent of weight loss itself. Full article

(This article belongs to the Special Issue Analytical Advances and Applications in Clinical Metabolomics)

► Show Figures

Figure 1

15 pages, 3600 KiB

Open AccessArticle

A Distinctive Metabolomics Profile and Potential Biomarkers for Very Long Acylcarnitine Dehydrogenase Deficiency (VLCADD) Diagnosis in Newborns

by Rajaa Sebaa, Reem H. AlMalki, Wafaa Alseraty and Anas M. Abdel Rahman

Metabolites 2023, 13(6), 725; https://doi.org/10.3390/metabo13060725 - 5 Jun 2023

Viewed by 1467

Abstract

Very long-chain acylcarnitine dehydrogenase deficiency (VLCADD) is a rare inherited metabolic disorder associated with fatty acid β-oxidation and characterized by genetic mutations in the ACADVL gene and accumulations of acylcarnitines. VLCADD, developed in neonates or later adults, can be diagnosed using newborn bloodspot screening (NBS) or genetic sequencing. These techniques have limitations, such as a high false discovery rate and variants of uncertain significance (VUS). As a result, an extra diagnostic tool is needed to deliver improved performance and health outcomes. As VLCADD is linked with metabolic disturbance, we postulated that newborn patients with VLCADD could display a distinct metabolomics pattern compared to healthy newborns and other disorders. Herein, we applied an untargeted metabolomics approach using liquid chromatography–high resolution mass spectrometry (LC-HRMS) to measure the global metabolites in dried blood spot (DBS) cards collected from VLCADD newborns (n = 15) and healthy controls (n = 15). Two hundred and six significantly dysregulated endogenous metabolites were identified in VLCADD, in contrast to healthy newborns. Fifty-eight and one hundred and eight up- and down-regulated endogenous metabolites were involved in several pathways such as tryptophan biosynthesis, aminoacyl-tRNA biosynthesis, amino sugar and nucleotide sugar metabolism, pyrimidine metabolism and pantothenate, and CoA biosynthesis. Furthermore, biomarker analyses identified 3,4-Dihydroxytetradecanoylcarnitine (AUC = 1), PIP (20:1)/PGF1alpha) (AUC = 0.982), and PIP2 (16:0/22:3) (AUC = 0.978) as potential metabolic biomarkers for VLCADD diagnosis. Our findings showed that compared to healthy newborns, VLCAADD newborns exhibit a distinctive metabolic profile, and identified potential biomarkers that can be used for early diagnosis, which improves the identification of the affected patients earlier. This allows for the timely administration of proper treatments, leading to improved health. However, further studies with large independent cohorts of VLCADD patients with different ages and phenotypes need to be studied to validate our potential diagnostic biomarkers and their specificity and accuracy during early life. Full article

(This article belongs to the Special Issue Analytical Advances and Applications in Clinical Metabolomics)

► Show Figures

Figure 1

Review

Jump to: Research

33 pages, 3564 KiB

Open AccessReview

COVID-19 and Comorbidities: What Has Been Unveiled by Metabolomics?

by André Luiz Melo Camelo, Hans Rolando Zamora Obando, Isabela Rocha, Aline Cristina Dias, Alessandra de Sousa Mesquita and Ana Valéria Colnaghi Simionato

Metabolites 2024, 14(4), 195; https://doi.org/10.3390/metabo14040195 - 30 Mar 2024

Viewed by 1386

Abstract

The COVID-19 pandemic has brought about diverse impacts on the global population. Individuals with comorbidities were more susceptible to the severe symptoms caused by the virus. Within the crisis scenario, metabolomics represents a potential area of science capable of providing relevant information for understanding the metabolic pathways associated with the intricate interaction between the viral disease and previous comorbidities. This work aims to provide a comprehensive description of the scientific production pertaining to metabolomics within the specific context of COVID-19 and comorbidities, while highlighting promising areas for exploration by those interested in the subject. In this review, we highlighted the studies of metabolomics that indicated a variety of metabolites associated with comorbidities and COVID-19. Furthermore, we observed that the understanding of the metabolic processes involved between comorbidities and COVID-19 is limited due to the urgent need to report disease outcomes in individuals with comorbidities. The overlap of two or more comorbidities associated with the severity of COVID-19 hinders the comprehension of the significance of each condition. Most identified studies are observational, with a restricted number of patients, due to challenges in sample collection amidst the emergent situation. Full article

(This article belongs to the Special Issue Analytical Advances and Applications in Clinical Metabolomics)

► Show Figures